Trial Profile
Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects With Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Feb 2024
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Cyclophosphamide (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms LYRA
- Sponsors Janssen
- 01 Oct 2022 Final results of the LYRA study published in the Leukemia and Lymphoma
- 17 Jun 2021 Results of updated analysis assessing safety and efficacy of daratumumab plus cyclophosphamide, bortezomib, and dexamethasone as an immunomodulatory drug-sparing regimen in newly-diagnosed patients with multiple myeloma (NDMM) and relapsed MM (RMM), presented at the 26th Congress of the European Haematology Association.
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology